vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and FTC Solar, Inc. (FTCI). Click either name above to swap in a different company.
FTC Solar, Inc. is the larger business by last-quarter revenue ($32.9M vs $18.7M, roughly 1.8× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -110.7%, a 109.9% gap on every dollar of revenue. On growth, FTC Solar, Inc. posted the faster year-over-year revenue change (148.9% vs -25.7%). FTC Solar, Inc. produced more free cash flow last quarter ($-8.4M vs $-15.8M). Over the past eight quarters, FTC Solar, Inc.'s revenue compounded faster (61.6% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
FTC Solar, Inc. is a leading global provider of advanced solar tracker systems, associated components, and supporting software for solar projects. It serves utility-scale, commercial, and industrial solar segments across key global markets, helping customers boost energy generation efficiency and lower overall project costs.
CTMX vs FTCI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $32.9M |
| Net Profit | $-154.0K | $-36.4M |
| Gross Margin | — | 14.9% |
| Operating Margin | -6.9% | -17.2% |
| Net Margin | -0.8% | -110.7% |
| Revenue YoY | -25.7% | 148.9% |
| Net Profit YoY | 97.6% | -197.4% |
| EPS (diluted) | — | $-2.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $32.9M | ||
| Q3 25 | — | $26.0M | ||
| Q2 25 | $18.7M | $20.0M | ||
| Q1 25 | $50.9M | $20.8M | ||
| Q4 24 | $38.1M | $13.2M | ||
| Q3 24 | $33.4M | $10.1M | ||
| Q2 24 | $25.1M | $11.4M | ||
| Q1 24 | $41.5M | $12.6M |
| Q4 25 | — | $-36.4M | ||
| Q3 25 | — | $-23.9M | ||
| Q2 25 | $-154.0K | $-15.4M | ||
| Q1 25 | $23.5M | $-3.8M | ||
| Q4 24 | $18.9M | $-12.2M | ||
| Q3 24 | $5.7M | $-15.4M | ||
| Q2 24 | $-6.5M | $-12.2M | ||
| Q1 24 | $13.8M | $-8.8M |
| Q4 25 | — | 14.9% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | — | -19.6% | ||
| Q1 25 | — | -16.6% | ||
| Q4 24 | — | -29.1% | ||
| Q3 24 | — | -42.5% | ||
| Q2 24 | — | -20.5% | ||
| Q1 24 | — | -16.7% |
| Q4 25 | — | -17.2% | ||
| Q3 25 | — | -29.6% | ||
| Q2 25 | -6.9% | -57.5% | ||
| Q1 25 | 44.4% | -50.8% | ||
| Q4 24 | 46.4% | -101.7% | ||
| Q3 24 | 12.3% | -147.8% | ||
| Q2 24 | -33.7% | -104.3% | ||
| Q1 24 | 28.1% | -99.3% |
| Q4 25 | — | -110.7% | ||
| Q3 25 | — | -92.0% | ||
| Q2 25 | -0.8% | -77.2% | ||
| Q1 25 | 46.2% | -18.4% | ||
| Q4 24 | 49.6% | -92.7% | ||
| Q3 24 | 17.2% | -151.5% | ||
| Q2 24 | -26.0% | -107.1% | ||
| Q1 24 | 33.3% | -69.7% |
| Q4 25 | — | $-2.31 | ||
| Q3 25 | — | $-1.61 | ||
| Q2 25 | — | $-1.18 | ||
| Q1 25 | — | $-0.58 | ||
| Q4 24 | — | $-0.95 | ||
| Q3 24 | — | $-1.21 | ||
| Q2 24 | — | $-0.97 | ||
| Q1 24 | — | $-0.70 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $21.1M |
| Total DebtLower is stronger | — | $9.9M |
| Stockholders' EquityBook value | $119.9M | $-43.0M |
| Total Assets | $175.1M | $111.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $21.1M | ||
| Q3 25 | — | $24.4M | ||
| Q2 25 | $49.0M | $3.5M | ||
| Q1 25 | $47.6M | $5.9M | ||
| Q4 24 | $38.1M | $11.2M | ||
| Q3 24 | $40.6M | $8.3M | ||
| Q2 24 | $43.2M | $10.8M | ||
| Q1 24 | $36.2M | $14.0M |
| Q4 25 | — | $9.9M | ||
| Q3 25 | — | $16.6M | ||
| Q2 25 | — | $10.9M | ||
| Q1 25 | — | $10.2M | ||
| Q4 24 | — | $9.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-43.0M | ||
| Q3 25 | — | $-13.7M | ||
| Q2 25 | $119.9M | $9.0M | ||
| Q1 25 | $25.0M | $15.5M | ||
| Q4 24 | $-456.0K | $19.0M | ||
| Q3 24 | $-23.5M | $30.4M | ||
| Q2 24 | $-31.2M | $44.2M | ||
| Q1 24 | $-31.7M | $55.2M |
| Q4 25 | — | $111.8M | ||
| Q3 25 | — | $111.5M | ||
| Q2 25 | $175.1M | $83.0M | ||
| Q1 25 | $98.5M | $84.1M | ||
| Q4 24 | $120.5M | $89.9M | ||
| Q3 24 | $139.0M | $91.7M | ||
| Q2 24 | $159.2M | $100.3M | ||
| Q1 24 | $184.7M | $115.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.20× | ||
| Q1 25 | — | 0.65× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-8.0M |
| Free Cash FlowOCF − Capex | $-15.8M | $-8.4M |
| FCF MarginFCF / Revenue | -84.6% | -25.7% |
| Capex IntensityCapex / Revenue | 0.1% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-34.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-8.0M | ||
| Q3 25 | — | $-14.6M | ||
| Q2 25 | $-15.8M | $-2.3M | ||
| Q1 25 | $-21.0M | $-8.5M | ||
| Q4 24 | $-19.9M | $-16.7M | ||
| Q3 24 | $-20.7M | $-2.4M | ||
| Q2 24 | $-19.5M | $-3.8M | ||
| Q1 24 | $-26.0M | $-11.9M |
| Q4 25 | — | $-8.4M | ||
| Q3 25 | — | $-15.1M | ||
| Q2 25 | $-15.8M | $-2.5M | ||
| Q1 25 | $-21.2M | $-8.6M | ||
| Q4 24 | $-20.0M | $-17.0M | ||
| Q3 24 | $-20.7M | $-2.6M | ||
| Q2 24 | $-19.6M | $-4.5M | ||
| Q1 24 | $-26.2M | $-12.3M |
| Q4 25 | — | -25.7% | ||
| Q3 25 | — | -57.9% | ||
| Q2 25 | -84.6% | -12.4% | ||
| Q1 25 | -41.6% | -41.2% | ||
| Q4 24 | -52.5% | -128.6% | ||
| Q3 24 | -62.1% | -25.6% | ||
| Q2 24 | -78.2% | -39.2% | ||
| Q1 24 | -63.1% | -97.6% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | 0.1% | 0.9% | ||
| Q1 25 | 0.2% | 0.4% | ||
| Q4 24 | 0.2% | 2.2% | ||
| Q3 24 | 0.1% | 2.2% | ||
| Q2 24 | 0.4% | 6.1% | ||
| Q1 24 | 0.3% | 3.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FTCI
| Products | $26.2M | 80% |
| Services | $6.7M | 20% |
